Wettersten Nicholas, Horiuchi Yu, Maisel Alan
Division of Cardiology, Veterans Affairs Medical Center, San Diego, CA, USA.
Division of Cardiovascular Medicine, University of California San Diego, La Jolla, CA, USA.
Fac Rev. 2021 Mar 31;10:34. doi: 10.12703/r/10-34. eCollection 2021.
Biomarkers are essential tools in the practice of cardiology. They assist with diagnosis, prognosis, and guiding therapy in many different cardiovascular diseases. Numerous biomarkers have become strongly associated with different cardiovascular conditions, such as troponin with acute coronary syndrome and natriuretic peptides with heart failure. Even though these biomarkers have been in practice for almost two decades, their uses continue to expand beyond their original roles. Additionally, many new biomarkers have been discovered with increasing utility in cardiovascular disease, including soluble suppression of tumorigenicity 2, galectin 3, and biomarkers of fibrosis, metabolism, and inflammation. How these old and new biomarkers are being expanded into clinical practice is constantly in evolution. This review will highlight some of the recent major advancements in the rapidly evolving field of biomarkers.
生物标志物是心脏病学实践中的重要工具。它们有助于多种不同心血管疾病的诊断、预后评估及治疗指导。众多生物标志物已与不同的心血管病症紧密相关,比如肌钙蛋白与急性冠脉综合征,利钠肽与心力衰竭。尽管这些生物标志物已应用近二十年,但其用途仍在不断拓展,超出了最初的作用范围。此外,人们还发现了许多新的生物标志物,它们在心血管疾病中的应用越来越广泛,包括可溶性肿瘤生长抑制因子2、半乳糖凝集素3以及纤维化、代谢和炎症的生物标志物。这些新旧生物标志物如何被应用于临床实践仍在不断演变。本综述将重点介绍生物标志物快速发展领域的一些近期主要进展。